We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
The product is now in the last stage of prototyping and will move to the verification and validation stages thanks to current fundraising.
MiMARK Diagnostics, S.L., a pioneering femtech spin-off from the Vall d'Hebron Research Institute (VHIR), has successfully raised €4.22 million as seed round stage. The substantial investment will drive the development of the company's groundbreaking gynecological diagnostics solutions, with key EU participation from the EIC Accelerator (European Innovation Council) and private investors, including Clave Capital, Nara Capital, Namarel Ventures, and WA4STEAM investing in May this year, and CDTI Innvierte, Inveready and Canterbury Scientific, joining on November 3rd. This diverse group of investors further strengthens the network of supporters backing MiMARK's vision
Marina Rigau, CEO and co-founder of MiMARK, expressed gratitude for the support received, stating, "This seed funding represents a significant milestone for MiMARK and validates our commitment to improve gynecological diagnostics. Thanks to this funding we will advance on bringing our first product to the market; an In Vitro Diagnostic for Endometrial Cancer. We are excited about the journey ahead and the positive impact our innovations will have on women's health."
The seed funding saw significant participation from the EIC Accelerator, with a total amount of 2.5 million, an initiative of the European Innovation Council dedicated to supporting innovative startups and SMEs.
MiMARK Diagnostics has achieved noteworthy milestones in the development of its flagship product, WomEC—an in vitro diagnostic test for endometrial cancer. WomEC is now in the last stage of prototyping and will move to the verification and validation stages thanks to current fundraising.
The newly secured funds will be instrumental in advancing MiMARK Diagnostics' mission to transform gynecological diagnostics, and especially to advance the first product to the market. Future plans include:
MiMARK Diagnostics, S.L. remains committed to improving women's health through innovation and scientific excellence.
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to firstname.lastname@example.org, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.